Ipsen Biopharmaceuticals, Inc.

464 articles with Ipsen Biopharmaceuticals, Inc.

• Ipsen delivers strong results for the first half of 2019 with robust double-digit sales growth and improved Core Operating margin and upgrades its guidance for full year 2019

  7/25/2019

  Ipsen, a global specialty-driven biopharmaceutical group, announced financial results for the first half of 2019.

• 

  Massachusetts Life Science M&A Hits $22.5 Billion So Far This Year

  7/10/2019

  As the largest center for biotech startups in the U.S., the Boston/Cambridge, Massachusetts area often acts as a marker for the entire industry. Here’s a look at the Massachusetts M&A deals so far.

• Ipsen and Servier Announce Initial Phase 1/2 Clinical Data Evaluating Liposomal Irinotecan (ONIVYDE®) as an Investigational First-line Treatment for Metastatic Pancreatic Cancer at ESMO 21st World Congress on Gastrointestinal Cancer

  7/5/2019

  Treatment emergent adverse events Grade 3 or higher were reported by 20 of 32 patients from the 50/60 dose pooled patient analysis; no patient reported Grade 3 or higher fatigue or peripheral neuropathy (primary endpoint)

• Ipsen Announces U.S. FDA Approval for Newly Designed Pre-Filled Syringe for Somatuline® Depot (lanreotide)

  6/24/2019

  Ipsen Biopharmaceuticals, an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), announced today that the United States Food and Drug Administration (FDA) has approved a new pre-filled syringe for Somatuline® Depot (lanreotide).

• Ipsen Celebrates Opening of New Cambridge Headquarters with Day of Service

  6/20/2019

  Ipsen officially opens North American headquarters at One Main Street and recently renovated R&D and Global External Innovation and Partnering facilities at 650 East Kendall Street

• Debiopharm and Ipsen Extend Their Strategic Decapeptyl® (triptorelin) Partnership for Another 15 Years

  6/12/2019

  Debiopharm and Ipsen extend and strengthen their ongoing collaboration to ensure patient access to Decapeptyl® for the treatment of certain urological, gynecological and pediatric conditions

• New Investigational Clinical Data for Ipsen’s Oncology Products in 11 Solid Tumor Types to Be Presented at 2019 ASCO Annual Meeting

  5/24/2019

  Ipsen announced that new data from clinical studies on investigational uses of cancer medicines cabozantinib, liposomal irinotecan, and lanreotide autogel will be presented at the 2019 American Society of Clinical Oncology Annual Meeting.

• Ipsen to Host an Investor Day to Highlight Its Innovative R&D Pipeline and Provide Financial Outlook for 2022

  5/14/2019

  Ipsen, a global specialty-driven biopharmaceutical group, will host an Investor Day in Paris to present a comprehensive corporate update, with a focus on its advancing R&D pipeline.

• Ipsen Reports Strong Double-Digit Sales Growth in First Quarter 2019 and Confirms Full Year 2019 Financial Targets

  4/24/2019

  Ipsen, a global specialty-driven biopharmaceutical group, announced its sales for the first quarter of 2019.

• Ipsen Completes Acquisition of Clementia Pharmaceuticals

  4/18/2019

  Ipsen’s Rare Diseases portfolio significantly enhanced with late-stage drug candidate, palovarotene, for the treatment of rare bone disorders in adult and pediatric patients

• SHAREHOLDER ALERT: WeissLaw LLP Investigates Clementia Pharmaceuticals, Inc.

  3/1/2019

  WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Clementia Pharmaceuticals, Inc. in connection with the proposed acquisition of the Company by French drugmaker Ipsen.

• Ipsen to Present New Data on Enhancement of Patient Care at the 16th European Neuroendocrine Tumor Society (ENETS) Annual Conference

  2/28/2019

  Studies Demonstrate Ipsen’s Ongoing Commitment to Innovation and Improving Patient Care in Neuroendocrine Tumors (NETs)

• Ipsen to Acquire Clementia Pharmaceuticals to Significantly Boost Rare Disease Portfolio

  2/25/2019

  Clementia’s late-stage drug candidate, palovarotene, has rare pediatric disease and breakthrough therapy designations for the treatment of an ultra-rare bone disorder and a path to approval in 2020

• 

  Ipsen Strikes Deal to Acquire Clementia for $1.31 Billion, Sends Stocks Soaring

  2/25/2019

  This morning, Ipsen said it entered into an agreement with Clementia will help the company continue its transformation that is part of a key strategic objective to accelerate its rare disease pipeline.

• Ipsen Delivers Strong 2018 Results and Expects Continued Sales and Profit Growth in 2019

  2/14/2019

  Ipsen, a global specialty-driven biopharmaceutical group, today announced its financial results for the full year 2018.

• 

  Top 12 Life Sciences Companies Hiring Now in February

  2/5/2019

  According to a BioSpace Community Survey, almost 70% of life sciences professionals plan to look for a new job in the next 12 months. Don't delay, accelerate your job search and check out top companies who are looking for quality candidates in 2019!

• Ipsen: Patients Living with Spasticity Want Long-lasting Symptom Relief

  1/18/2019

  International survey presented at TOXINS 2019 reveals hidden burden of spasticity

• Ipsen Presents the Results of the First in-Human Study of a Recombinant Fast-Acting Neurotoxin (rBoNT-E) at TOXINS 2019

  1/17/2019

  Safety, tolerability and pharmacodynamics of BoNT-E demonstrated in Phase I study

• 

  Top 10 Cities in the U.S. for the Job Market

  1/15/2019

  New Year, fresh start? Could be. WalletHub recently compared more than 180 cities across the U.S., using 30 key indicators to evaluate their job strength. Some of those factors were job opportunities, employment growth, monthly average starting salary and employment outlook.

• Ipsen demonstrates leadership position in neurotoxin research with strong presence at TOXINS 2019

  1/11/2019

  Ipsen announced that abobotulinumtoxinA (Dysport®) and its recombinant botulinum toxins pipeline are the subject of 50 posters at the 2019 TOXINS International Conference.